What are the Major Trends in the Biochip Market?

• In March 2024, Randox Laboratories launched the world's first genetic test on a biochip designed to rapidly identify individuals at high risk of developing type 1 diabetes. This test allows for early, preventative medical intervention based on a patient's genetic profile.
• In April 2024, Boston Micro Fabrication (BMF) Biotechnology Inc. launched this new division that specializes in high-resolution 3D-printed organ-on-a-chip platforms
• In January 2025, Coherent Corp. introduced advanced pin-hole array biochips for gene sequencing applications
  

  What is the Emerging Challenge in the Biochip Market?

  The market is mainly facing a hurdle, including high manufacturing costs, complex regulatory hurdles, and technical issues related to reproducibility. Overcoming these barriers will be crucial for the widespread adoption and future expansion of biochip technologies across various applications.

  Become a valued research partner with us -

  Regional Analysis

  How did North America Dominate the Market in 2024?

  In 2024, North America captured the biggest revenue share by 40% of the market. The advanced healthcare infrastructure and substantial R&D investments. The presence of major biotechnology and pharmaceutical companies

  For instance,

  • In September 2024, Nomic Bio, a US protein profiling company, secured $42 million in Series B funding to expand its commercial operations and enhance its protein profiling platform, illustrating significant private investment within the North American market.
    

  Why did Asia Pacific Grow Notably in the Market in 2024?

  Asia Pacific is anticipated to expand at a rapid CAGR during 2025-2034 in the biochip market. The significant increases in healthcare expenditure and robust government funding for biotechnology R&D. The region benefits from a large patient population, a rising focus on personalized medicine, and supportive policies that facilitate technology adoption.

  For instance,

  • In September 2024, the Indian government sanctioned over 10 billion rupees (1000 crores) to accelerate innovation in biotechnology, directly supporting the R&D and adoption of advanced tools like biochips.
    

  US FDA and EMA: Approved Biochip in 2024-2025

  US FDA
  Oncomine Dx Target Test	For certain cancers, an approval expansion.
  TruSight Oncology Comprehensive	For comprehensive genomic profiling in cancer patients, utilizing advanced sequencing technology.
  BD Onclarity HPV Assay and cobas HPV Tests	For use on automated systems, which are essentially sophisticated lab-on-a-chip or microfluidic systems that automate sample processing, amplification, and detection.
  EMA
  Integration of "Organ-on-a-Chip"	For New Approach Methodologies (NAMs), such as "organ-on-a-chip" technology.
  Diagnostic Test Systems	For marketing authorixation.

  Get the latest insights on life science industry segmentation with our Annual Membership:

  Segmental Insights

  By chip type/product analysis

  Which Chip Type/Product Led the Biochip Market in 2024?

  The DNA microarrays/DNA chips segment accounted for a dominant share of the market in 2024. Their established reliability, cost-effectiveness for targeted analyses, and the ability to perform high-throughput screening of thousands of genes simultaneously. Their extensive applications in diagnostics, genomics research
  However, the lab-on-a-chip/microfluidic platforms segment is predicted to expand at a lucrative CAGR. The accelerating demand for portable and cost-effective point-of-care diagnostics

  By offering/product category analysis

  What Made the Instruments & Readers Segment Dominant in the Market in 2024?

  The instruments & readers segment held a major revenue share of the biochip market in 2024. These instruments represent a significant upfront capital investment for the end user, distinguishing them from the recurring, smaller purchases of biochip consumables. The continued demand from biotechnology, pharmaceutical, and diagnostic sectors, which require robust hardware for research and clinical applications, further solidifies the instruments and readers, fuelling the market growth.

  However, the software & data analytics segment is estimated to expand rapidly in the predicted timeframe. It plays an essential role in translating the massive, complex datasets generated by biochips into actionable clinical and research insights. The integration of advanced AI and machine learning algorithms enhances diagnostic accuracy and automates analysis workflows. The demands of personalized medicine and accelerating drug discovery

  By application/end analysis

  What Made the Clinical Diagnostic Segment Dominant in the Market in 2024?

  The clinical diagnostic segment held a major revenue share of the biochip market in 2024. The high demand for rapid, precise, and cost-effective disease detection and monitoring tools. The rising global prevalence of chronic diseases and the shift towards personalized medicine necessitate advanced diagnostic solutions that biochips efficiently provide. The demand for point-of-care testing and integration into existing healthcare systems further solidified the market growth.

  On the other hand, the point-of-care testing segment is estimated to expand rapidly in the predicted timeframe. The high demand for rapid, portable, and accessible diagnostics outside of centralized laboratories
  • In October 2025, the Indian government launched the Maha MedTech Mission with substantial funding to support innovation in medical technology, including point-of-care molecular diagnostics.
    

  By technology/platform analysis

  What Made the Microarray-based Segment Dominant in the Market in 2024?

  The microarray-based segment held a major revenue share of the biochip market in 2024. Due to its widespread application in diagnostics, genomics research, and pharmacogenomics solidified its position as a foundational tool. The cost-effectiveness of microarrays for specific large-scale studies, coupled with continuous product innovation from major industry players, further fuels the market growth.

  However, the microfluidics/lab-on-a-chip segment is estimated to expand rapidly in the predicted timeframe. Due to its inherent advantages in portability, automation, and efficiency for point-of-care diagnostics. The integration of advanced technologies like AI and organ-on-a-chip models is also driving innovation and application in drug discovery and personalized medicine.

  By end-user/buyer analysis

  What Made the Clinical Laboratory & Hospitals Segment Dominant in the Market in 2024?

  The clinical laboratories & hospitals segment held a major revenue share of the biochip market in 2024. Their critical need for rapid, accurate, and advanced diagnostic tools for chronic diseases, combined with the integration of biochip technology into existing automated workflows and the growing adoption of personalized medicine, drove this leadership.

  On the other hand, the point-of-care providers/clinic segment is estimated to expand rapidly in the predicted timeframe. The high demand for rapid, accessible, and decentralized diagnostics. The need for immediate clinical decision-making, the increasing burden of chronic diseases, and technological advancements in portable devices. As healthcare shifts towards more convenient and efficient patient care models, clinics are becoming primary users of PoC biochips, ensuring the expansion.

  Browse More Insights of Towards Healthcare:

  The global protein chip market

  The kidney organ-on-a-chip market

  The digital microfluidics systems-on-a-chip market

  The global breast cancer screening tests market

  The cellular health screening market

  The chromatography accessories and consumables market

  The IVD diagnostic molecule raw enzymes market

  The cancer biomarkers market

  The MRI (Magnetic Resonance Imaging) market

  The Pre-Dx oncology market

  What are the Revolutionary Developments in the Biochip Market?

  • In September 2025, Advanced Biomed Inc. launched this compact, all-in-one perfusion 3D cell culture incubator system, designed to replicate human physiological conditions in vitro for precision medicine and diagnostics.
  • In April 2025, CN Bio and Pharmaron Partnership announced this collaboration aims to advance organ-on-a-chip (OOC) drug discovery by installing CN Bio's PhysioMimix instruments at Pharmaron's global facilities for the joint development of OOC solutions.

  Biochip Market Key Players List

  • Numerous specialty microfluidics & startup innovators
  • Bio-Rad Laboratories
  • Akoya Biosciences
  • Danaher Corporation (Cepheid, Beckman Coulter)
  • Siemens Healthineers
  • Qiagen
  • LGC Group / Randox (regional niche)
  • GE Healthcare / Cytiva
  • BioMérieux
  • Fluidigm (Standard BioTools)
  • NanoString Technologies
  • Micronit
  • Phalanx Biotech
  • Abbott Laboratories

  Segments Covered in this Report

  By Chip Type / Product

  • DNA Microarrays / DNA Chips
  • Protein Chips / Proteomics Arrays
  • Lab-on-a-Chip / Microfluidic Platforms
  • Tissue / Cell Arrays
  • Enzymatic & Biosensor Chips
  • Others
  • Consumables/Reagents & Software
    

  By Offering / Product Category

  • Instruments & Readers
  • Consumables / Disposable Chips & Cartridges
  • Reagents & Kits
  • Software & Data Analytics

  By Application / End Market

  • Clinical Diagnostics
  • Drug Discovery & Pharma R&D
  • Genomics & Research
  • Point-of-Care Testing
  • Environmental & Food Testing
    

  By Technology / Platform

  • Microarray-based platforms
  • Microfluidics / Lab-on-a-chip
  • NGS-compatible prep chips/sequencing sample-prep modules
  • Biosensors & Electrochemical chips
  • Optical / plasmonic & specialty nanotech chips
    

  By End User / Buyer

  • Clinical Laboratories & Hospitals
  • Pharmaceutical & Biotech R&D
  • Point-of-care providers / Clinics
  • Academic & Research Institutes
  • Environmental / Food & Safety Labs
    

  By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
      
  Immediate Delivery Available | Buy This Premium Research @

  Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

  Access the Dashboard:

  About Us

  Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research
  You can place an order or ask any questions, please feel free to contact us at ...

  Europe Region: +44 778 256 0738

  North America Region: +1 8044 4193 44

  APAC Region: +91 9356 9282 04

  Web:

  Our Trusted Data Partners

  Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
  Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest